NCPIC now offers PYLARIFY (piflufolastat F-18) for PET scans!
PYLARIFY injection is a radioactive diagnostic agent indicated for PET imaging of prostate specific membrane antigen (PSMA) positive lesions in men with prostate cancer.
PYLARIFY is indicated for assessing patients with:
- suspected prostate cancer metastasis who are candidates for initial therapy OR
- Suspected recurrence based on elevated PSA
Because this new approval is not limited to recurrent prostate cancer, PSMA imaging can be considered as an alternative to standard bone and soft tissue imaging for initial staging.
The ability to offer PSMA scans in the community is a very exciting development for all of us who have anticipated Medicare approval and dose availability.
You can also visit www.pylarify.com to learn how PYLARIFY PET scans may assist in treatment decisions.